MONMOUTH JUNCTION, N.J. - Sept. 8, 2016 - PRLog -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for improving the proteomic information obtained from bronchoalveolar lavage fluid (BALF). The citation is:
Maneesh Bhargava, Kevin J. Viken, Sanjoy Dey, Michael S. Steinbach, Baolin Wu, Pratik D. Jagtap, LeeAnn Higgins, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Vipin Kumar, Mukta Arora, Peter B. Bitterman, David H. Ingbar, Chris H. Wendt. Proteome Profiling in Lung Injury after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22 (2016) 1383-1390.
www.bbmt.org/article/S1083-8791(16)30060-X/fulltext
The authors consider pulmonary complications due to infection and idiopathic pneumonia syndrome (IPS) in hematopoietic stem cell transplant (HSCT) recipients. For this, a proteomic characterization of global bronchoalveolar lavage fluid (BALF) was studied to identify proteins and pathways that differentiate IPS from infectious lung injury after HSCT. Because the BALF samples appeared tinged with blood, the authors tested HemogloBind™ to determine whether the removal of hemoglobin (in addition to high-abundance proteins) would improve the depth of coverage. The article states “Hemoglobin removal improved protein identification to 845 proteins at 1% global FDR compared with 496 proteins with high-abundance protein depletion alone”. The authors conclude that the protein expression differences provide insights into mechanisms activated in lung injury and suggest potential therapeutic targets to augment lung repair.
“I am very pleased that this article demonstrates the proteomic utility of removing hemoglobin from tissue samples containing small amounts of blood. It is very impressive that the use of HemogloBind™ improved the depth of coverage by almost 2-fold” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
For more information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin...
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com
Contact:
Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
sales@biotechsupportgroup.com
http://www.biotechsupportgroup.com
